Zurzuvae PPD denied as non-formulary by Aetna?

Aetna's specific coverage criteria for zurzuvae ppd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Zurzuvae for PPD as Non-Formulary

Aetna places Zurzuvae (zuranolone) on a restricted or non-formulary tier on many of its commercial and marketplace plans. A non-formulary denial means the plan will not cover the drug at any standard cost-sharing level without additional authorization — it does not mean the drug is ineligible for coverage entirely. Most plans have a formal exceptions process specifically for non-formulary medications.

## Why This Denial Is Appealable

Under ACA §2719 and applicable state insurance law, you have the right to request a formulary exception whenever a covered drug does not meet your clinical needs, a formulary alternative is contraindicated or has been ineffective, or the treating clinician documents that the requested drug is medically necessary. Zurzuvae's distinct mechanism and FDA-approved indication for postpartum depression provide a clinical basis for arguing that formulary alternatives are not therapeutically equivalent for this patient.

## Federal and Plan Appeal Framework

• Formulary exception request: File this with Aetna's pharmacy benefit department as a first step, supported by a prescriber letter. This is often faster than a formal internal appeal.
• Internal appeal: If the exception is denied, submit a formal internal appeal within the deadline in your denial notice. Request the specific formulary exception criteria in writing so you can respond to each.
• External review: After a final internal denial, you have approximately 4 months to request independent external review under ACA §2719. An accredited IRO reviews the clinical record independently of Aetna.
• Expedited review: Available if delay poses a serious health risk; turnaround is required within 72 hours.

## Documentation to Gather

1. Diagnosis and indication confirmation: DSM-5 documented PPD diagnosis with onset timing, from the treating provider. 2. Formulary alternative trial history: For each antidepressant Aetna lists as a formulary alternative, document whether it was tried, the outcome, and the reason it is not appropriate now — supported by chart notes and prescriber attestation. 3. Clinical rationale for Zurzuvae specifically: Prescriber letter explaining the clinical reasons this patient requires Zurzuvae rather than a formulary alternative, tied to the FDA-approved indication and the relevant professional society guideline. 4. Safety or tolerability documentation: Any documented adverse effects, clinical contraindications per the prescribing label, or safety concerns that make formulary alternatives inappropriate for this patient. 5. Aetna's formulary exception criteria: Obtain these in writing from Aetna and map each criterion to a specific chart fact in your appeal.

## Criteria-Mapping Structure

For every exception criterion Aetna lists, include in your appeal:

• Criterion (verbatim): [Aetna's exact language]
• Patient evidence: [specific chart note, date, clinician, and outcome]

A clear, criterion-by-criterion response significantly increases the probability of a successful formulary exception or internal appeal outcome. Attach prescriber notes and relevant medical records as labeled exhibits.